A study published in Translational Psychiatry indicates that low systemic (plasma) levels of the repressor element 1-silencing transcription (REST) factor represent a candidate biomarker of cognitive decline and Alzheimer’s disease (AD). The study also suggests that low systemic REST levels may be associated with a poor brain stress protection during aging.
In the Translational Psychiatry study, NJ Ashton and colleagues from the Institute of Psychiatry, Psychology and Neuroscience, King’s College London, UK report that the blood plasma REST levels are reduced in AD compared to healthy elderly controls (HECs).
The researchers found that patients with mild cognitive impairment (MCI) who later converted to AD had low plasma REST levels, whereas nonconverters or participants with stable MCI had a REST levels comparable to healthy control individuals.
Of note, and as discussed by the authors it remains unclear whether the peripheral blood REST measured in their study reflects levels in the central nervous system.
The authors also used mindfulness-based stress reduction (MBSR) intervention, demonstrating that REST levels can be modulated through this relatively brief intervention, and that changes in REST are associated with clinical improvements. Importantly, they report that in older adults at risk of developing dementia, a significant increase in REST levels was induced by a stress reduction intervention after 8 weeks.
The authors conclude that “determining REST in blood provides a prognostic marker that can help stratify patients for inclusion in trials, identify those at high risk of ‘stress-induced’ cognitive decline and determine the efficacy of therapeutic interventions”.